What Happened?
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) jumped 18.2% in the afternoon session after the company reported second-quarter results that showed improved profitability and a narrower-than-expected loss per share.
The company's revenue grew 5.8% year on year to $254.6 million, meeting Wall Street’s expectations. The key driver for the positive sentiment appeared to be improved profitability. Tandem's operating margin improved significantly to -5.4% from -21.5% in the same quarter last year, and its adjusted EBITDA of $6.42 million was well ahead of the $3.52 million consensus estimate. The company's reported GAAP loss of $0.31 per share was also slightly better than anticipated. Additionally, Tandem reaffirmed its full-year revenue guidance with a midpoint of $1.08 billion.
The shares closed the day at $22.37, up 19.1% from the previous close.
Is now the time to buy Tandem Diabetes? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Tandem Diabetes’s shares are extremely volatile and have had 49 moves greater than 5% over the last year. But moves this big are rare even for Tandem Diabetes and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 30.2% on the news that the company reported better-than-expected fourth-quarter financial results. The medical device maker posted quarterly sales of $290.4 million, a 15% increase year-on-year that surpassed analyst estimates. The company also recorded a much smaller-than-expected loss of just one cent per share. While this was a slight decline from the one-cent profit reported in the same quarter last year, it handily beat forecasts. Investors appeared to focus on the strong quarterly performance and improved operating margins, driving the stock higher despite the company issuing a 2026 sales forecast that was slightly below market expectations.
Tandem Diabetes is up 3.9% since the beginning of the year, but at $22.39 per share, it is still trading 20.8% below its 52-week high of $28.26 from February 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Tandem Diabetes’s shares 5 years ago would now be looking at only $207.87.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
